Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

Chris Twelves, A. Wong, Marek P. Nowacki, Markus Abt, Howard A. Burris, Alfredo Carrato, Jim Cassidy, Andrés Cervantes, Jan Fagerberg, Vassilis Georgoulias, Fares Husseini, Duncan I. Jodrell, P. Koralewski, H. Kröning, Jean A. Maroun, Norbert Marschner, Joseph McKendrick, Marek Pawlicki, Riccardo Rosso, Johannes Schüller, Jean‐François Seitz, Borut Štabuc, Jerzy Tujakowski, Guy van Hazel, J. Załuski, Werner Scheithauer

New England Journal of Medicine, 2005

University of Glasgow, Cancer Research UK, University of Leeds, Bradford Teaching Hospitals NHS Foundation Trust, The Maria Sklodowska-Curie National Research Institute of Oncology, Roche (Switzerland), Hospital General Universitario de Elche, University of Aberdeen, Hospital Clínico Universitario de Valencia, University Hospital of Heraklion, Hôpital Pasteur, University of Edinburgh, Klinikum Magdeburg, Ottawa Regional Cancer Foundation, University Medical Center Freiburg, Box Hill Hospital, Krakow Cardiovascular Research Institute, Alleanza Contro il Cancro, Krankenanstalt Rudolfstiftung der Stadt Wien, Hôpital de la Timone, Ljubljana University Medical Centre, University of Bydgoszcz, Mount Medical Centre, Greater Poland Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1246

Citations

View on Google Scholar

Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back